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TISSUE CULTURE STUDIES IN THE UROLOGICAL FIELD，
  PARTICULARLY IN A RELATION TO THE FIBRINOLYTIC
  SYSTEM IN CANCER AND ITS CLINICAL IMPLICATIONS
                                 Haruo HisAzuMi
Coworkers： MisAKI， T．， NAiTo， K．， TAyA， T．， UcHIBAyAsHI， T．， TsuKAHARA， K．，
       KoBAyAsHI， rlr．， NAKAGIMA， K．， KATo， M．， SAIToH， Y．， KolzuMI， H．，
                          NisHiNo， A． and KosHiDA， K．
             From the DePartment of Urology， School qf Medicine， Kanazawa University
                              （Director： Prof． K． KurodaJ
   In this special lecture presented were the results of tissue culture studies of urological canCers
in our department， The tissue cultures have been introduced into our experimental investigations
of the’ fibrinolytic system in neoplasms， particularly bladder cancer， and of an in vitro sensitivity test
ofanticahcer drugs． ln addition， the results of our clinically significant studies related to the fibrinolytic
system in the diagnostic and therapeutic aspects of bladder cancer were reported．
   Using a micro－single radial immunodiffusion method， serum protease inhibitors including a1一
antitrypsin， crrantichymotrypSin and Cls－inhibitor were increased， whereas plasrninogen was decreased
in bladder cancer patients． These changes were rernarkable in patients with an advanced bladder
c耳ncer and出e decrease ofα2－macroglobulin， a distinct condition in DIC， was also fbund． The dc－
prcssed fibrinolytic activity indlcqted． by these results wopld be a predisposing cause offibrin depositions
in cancerous tissues or blood vessels， and explain that patients with an advanced tumor are prone
to develop vascu14r thrombosis and terid to occur a peculiar form of intravascular coagulation．
   During last 6 years， 75 out of 172 human urological malignant tumors subjected to tissue culture
studies were successed in a primary culture， and 2 cell lines， KK－47 and KW－103， derived from tran－
sitional cell carcinomas of the bladder， and 2 cell lines， KN－41 and KH－39， from renal cell carcinomas，
have been established and these cell lines utilized for the subsequent studies．
   Three human bladder carcinoma cell lines， T24， RT4 and MANO， a human bladder non－malig－
nant epithelial cell line， HCV－29， and a human lung’ fibroblast line， 460 HI， were investigated for
their ability to induce fibrinolytic， urokinase and plasmin inhibitory activities in cell culture， using
serum－free medium， for up to 36 hrs． Generally， the non－malignant cell line and the fibroblast line
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had a greater ability to produce urokinase inhibitor than did the malignant ce！1 lines． The low con－
centration of plasminogen activator， immunologically identical with urokinase， and its accumulation
in culture supernatant were found wit．h RT4 after 12－hr and 24－hr cultivations， whereas no plasminogen
activator was detected in all other cell lines for periods up to 36 hrs． No plasmin， non－specific protease
or plasmin inhibitory activities were detected in any of the supernatants from the cell lines． Moreover，
i251－fibrin coated culture dishes were adopted for a meticulous detection of in vitro plasminogen activator
production by cultured cells in Ham F 12 medium supplemented with 20 per cent calf serum． ln
this assay system， KK－47， KW－103 and KN－41 cells tesulted in an accumulation ofplasminogen activator
ih the medium along with their logarithmic cell growth curves． However， in case of culture dishes
not coated by fibrin， a temporary production of plasminogen activator o．ccurred for the first 24 hrs
of culture periods， and then a progressive lowering of the production was found in spite of their loga－
rithmic cell proliferation． These in vitro results suggested that the activator production by cultured
cells may be stimulated by thg coexistence of fibrin and it may．overcome the activity of fibrinolysis
inhibitors． This suggestion would be able to explain a mechanism between the・production and elimi－
nation of fibrin depositions in cancerous tissues and a rapid turnover of fibrinogen or fibrin in cancer
patients． Clinically， the presence of this turnover would be manifested by an increased urinary FDP
in bladder cancer patients， and urinary FDP would be considered as a biochemical marker in blqdder
cancer．
    Enhanced cell killing effect by thio－TEPA and urokinase on KK－47 cells was investigated using
methods of assessing cell growth and 3H－thymidine uptake． A combined use of urokinase and thio－
TEPA resulted in a significant increase of the thio－TEPA toxicity with a 2－hr and 24－hr exposure
times． A peak in 32P－thio－TEPA uptake in the cells was observed 2 hrs after administration of the
agent， and about 2－time increase in the peak was obtained by adding urokinase． From the results，．
it was suggested that the increased cytotoxicity may be related with a gross change in cell permeability
to thio－TEPA through plasminogen activation by urokinase． This conclusion was introduced into
the topical prophYlactic combination use of thio－TEPA， carboquone or cytosine arabinoside and
urokinase in bladder cancer patients． The recurrence rates of the thio－TEPA and carboquone therapies
for the postoperative 12 months were 10 and 14 per cent， and 22 and 33 per cent for the postoperative
24 months， respectively． While， combined instillation of cytosine arabinoside， a time－dependent
anticancer agent， and urokinase resulted in high recurrence rates， 24．0 and 33．5 per cent for the post“
operative 3 and 6 months， respectively． These data would recommend the topical use ofdose－dependent
anticancer agents such as alkylating agent and antibiotic rather than time－dependent anticancer agents．
    KK47， KW－103 and KN－41 were used for studies’ on the cytocidal effect of 7 anticancer agents，
The effect on in vitro cultured cells was determined by a colony－forming method． Based on 50 per
cent and 90 pcr cen口cthal dosages in 2－hr and 24－hr exposures， the most prominent cytocidal effect
on the cells was obtained by carboquone， adriamycin and mitomycin C． A inild cell killing effect
was obtained by cis－platinum， VP－16， bleomycin and thio－TEPA． There were slight differences
of cell killing effect among the cell lines， and the survival curves characteristic in cell killing modality
would provide a valuable reference for their clinical use． The in vitro cytotoxicity of anticancer drugs
should be compared with their clinical benefits and the improvement of the test system including much
more significant cell lines is necessary to establish its clinical usefulness．
    Enhanced cell killing effect by t－AMCHA， a potent antiplasmin agent， and carboquone or bleo－
mycin on KK－47， KW－103 and KN－41 cells was investigated using the colony－forming method． The
effect was observed in the combinations of 50 per cent lethal dose of the agents and 150’to 1500 pg／ml
of t－AMCHA． Much more clearly enhanced cell killing effect was also obtained in combination
with another most potent antiplasmin agent， DV－IOO6， and these anticancer agents． While， EACA，
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a relatively weak antiplasmin agent compared with t－AMCHA or DV－1006， possessed less combination
effect． lt is certain that an enhanced inhibitory action for the cell growth is achieved by combination
of anticancer drugs and induced antifibrinolysis． However， further in vivo studies of the combination
are necessary to clarify the role of antifibrinolysis in the combination effect．
  A future new promising plan for tissue culture studies with regard to the development of diagnosis
and treatrnent of bladder cancer was discussed．
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0’Mcara（1958）…・…・・癌細胞のcancer coagulative
           factorと癌組織ブイプリン沈
           着
Grossi et al．（1960）…・■■実験腫瘍の転移をプラスミン
           が抑制
三瀬腰ll｝……雅野辺のブイプリン漉
Mutschlcr＆Bale（1962）担癌動物のブイブリノーゲン
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Fig． 1． Microscopic section of bladder cancer demonstrates multiple micro－fibrin
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Fig． 2．Inverted microscopic photograph showing growing cells of
KH－39 after 4 days in culture． Reduced from × 200．
Fig． 3．Inverted micr scopic photcgraph showing growing cells of KN－








Fig． 4．Inverted microscopic photograph showing growing cells of
KK－47 after 3 days in culture． Reduced from × 200．
Fig． 5．Inverted microscopic photograph showing growing cells of
























































































HeLa o o o 42．2 FC－20
Table 7．培養液上清中のurokinase inhibitory
activity
   Table 8．培養期間と培養細胞数
Cell line Cultivation period under serum－tree condiSon
Urokinase inhibitory activlty 12 hrs 24 hrs 48 hrsNote
Tissue ： No．
・ CTA units／rn1CTA units／mレLOxlO4 cells
Rena［ ce［1 carcinoma
    DK5－K2
    DK5－K6
    DK8－Kg
    DKIO－KH
    KK2－K4
    KK9－K18
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Table 9．培養液上清中urokinase inhibitory activity
      （the fibrin plate method｝
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     細胞増殖抑制
Number of cells （xlO4ceils／ml）
Exposure time
2hrs 24hrs 72hrs
  Control     2L9±i．0  21．9士1．0  22．O土i．2
Urokinase｛IOCTAu／ml｝ 22．7士L7 22，6±O．9  2 L7士LO
Thio－TEPA｛10pg／mU  9．9士Ll  7．6土○．6  6．5士Q7







V2 2 5 6hr＄
Uroklnose
 l CTA u／ml
 10
100
46．8：と5，0 73、5一士「8．0 59．2ま：IO．4  6i．7±16」2  54．3圭3，3
60．O士9．2  928±13．O  i297土lQ8  115．7士9」   98．8士22．0
78．2土9．8  98．5士2Q8  95．1土16．0  578士6．8  63．8士［7【
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   QO I QO5 O．1 02 05      Concentrations of Adriamycin PglMl
Fig． 9． Survival curve of KW－103 cells exposed
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     細胞効果
o
Fig． I l．
exposure time 5Pr50｛Pgil18h rIDgOり」9／mけ
2hr ’ 24hr
Thio－TEPA 7，6 1．OBIeomycin 2．4 2．9xbO’i
             －lNK一 65L 2．0 2．OxlO
vP－16 1．7 1，7xlO一＋
cis－PLatinum 1．5 2．9xto－i




















     殺細胞効果

























 O．5 1 2 3 Concentrations of CQ （pg／ml）
Survival curves of KK－47 cells exposed
to different concentrations of carbazil－
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目K－47細胞におけるcarbazilquinoneの殺細胞効
果に対するt－AMCHAの増強効果





























1）Jurgens， R． and Trautwein， H・：Uber Fibrino－
 penie （Fibrinogenopenie） beim Erwachsenen，
 nebst Bermerkungen uber die Herkunft des




 術， 14＝92豆～927， 1960．
3）黒田恭 一・久住治男：泌尿器科領域における線溶
 系．最新医学，21：296～306，1966．
4） Hisazumi， H．， Uchibayashi， T．， Naito， K．，
 Misaki， T． and MiYazaki， K．： The prophylactic
 use of thio－TEPA and urokinase in transitional
 cell carcinoma of the bladder： a preliminary
 report． J． Urol．， 114： 394一一S98， 1975．
5） Tagnon， H．J．， Whitmore， W．F．， Jr．， Schulman，
  ？． and Kravitz， S．C．： Significance of fibrinolysis
  occurring in patients with metastatic cancer of





  糸己要， 26＝265～271， 1980．
8） Hisazumi， H．： Studies on the fibrinolytic
  qctivity in cancerous tissues： a study by gel











12） Williams， R．D．： Human urologic cancer cell
  lines． lnvest． Urol．， 17： 359一一363， 1980．
13） Hisazumi， H．， Andersson， L． and Collins， V．P．：
  Fibrinolytic activity of in vitro cultivated human
  bladder cell lines． Urol． Res．，5； 133N139， 1977．
14）大滝三千雄：泌尿器悪性腫瘍における血清および






















  ついて，第1報癌と化学療法，6： 1057～1062，
  1979．
20） Astedt， B．， Gilfberg， 1．， Mattsson， W． and Trope，
  C．： Arrest of growth of ovarian tumor by
  tranexamic acid． J．A．MA， 238： 154一一155，
  1977．
21） Astedt， B．， Mattsson， W． and Trope， C．： Treat－
  ment of advanced breast cancer with chemo－
  therapeutics and inhibition of coagulation and
  fibrinolysis． Acta Med． Scand．， 201： 491・一493，
  1977．
22）中嶋和喜：ヒト膀胱癌由来培養細胞（KK－47
  細胞）における温熱および放射線による殺細胞効
  果の研究．日泌尿会誌，71：363～377，1980．
